These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 25825724)

  • 21. Identification of Novel Small Molecule Ligands for JAK2 Pseudokinase Domain.
    Virtanen AT; Haikarainen T; Sampathkumar P; Palmroth M; Liukkonen S; Liu J; Nekhotiaeva N; Hubbard SR; Silvennoinen O
    Pharmaceuticals (Basel); 2023 Jan; 16(1):. PubMed ID: 36678572
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.
    Roskoski R
    Pharmacol Res; 2016 Sep; 111():784-803. PubMed ID: 27473820
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activating JAK2 mutants reveal cytokine receptor coupling differences that impact outcomes in myeloproliferative neoplasm.
    Yao H; Ma Y; Hong Z; Zhao L; Monaghan SA; Hu MC; Huang LJ
    Leukemia; 2017 Oct; 31(10):2122-2131. PubMed ID: 28057939
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of JAK1 Pseudokinase Domain in Cytokine Signaling.
    Raivola J; Haikarainen T; Silvennoinen O
    Cancers (Basel); 2019 Dec; 12(1):. PubMed ID: 31892268
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling.
    Ungureanu D; Wu J; Pekkala T; Niranjan Y; Young C; Jensen ON; Xu CF; Neubert TA; Skoda RC; Hubbard SR; Silvennoinen O
    Nat Struct Mol Biol; 2011 Aug; 18(9):971-6. PubMed ID: 21841788
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Akt activation through the phosphorylation of erythropoietin receptor at tyrosine 479 is required for myeloproliferative disorder-associated JAK2 V617F mutant-induced cellular transformation.
    Kamishimoto J; Tago K; Kasahara T; Funakoshi-Tago M
    Cell Signal; 2011 May; 23(5):849-56. PubMed ID: 21255641
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Insights on JAK2 Modulation by Potent, Selective, and Cell-Permeable Pseudokinase-Domain Ligands.
    Liosi ME; Ippolito JA; Henry SP; Krimmer SG; Newton AS; Cutrona KJ; Olivarez RA; Mohanty J; Schlessinger J; Jorgensen WL
    J Med Chem; 2022 Jun; 65(12):8380-8400. PubMed ID: 35653642
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular basis for pseudokinase-dependent autoinhibition of JAK2 tyrosine kinase.
    Shan Y; Gnanasambandan K; Ungureanu D; Kim ET; Hammarén H; Yamashita K; Silvennoinen O; Shaw DE; Hubbard SR
    Nat Struct Mol Biol; 2014 Jul; 21(7):579-84. PubMed ID: 24918548
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery and Structural Characterization of ATP-Site Ligands for the Wild-Type and V617F Mutant JAK2 Pseudokinase Domain.
    McNally R; Li Q; Li K; Dekker C; Vangrevelinghe E; Jones M; Chène P; Machauer R; Radimerski T; Eck MJ
    ACS Chem Biol; 2019 Apr; 14(4):587-593. PubMed ID: 30763067
    [TBL] [Abstract][Full Text] [Related]  

  • 30. JAK2 V617F constitutive activation requires JH2 residue F595: a pseudokinase domain target for specific inhibitors.
    Dusa A; Mouton C; Pecquet C; Herman M; Constantinescu SN
    PLoS One; 2010 Jun; 5(6):e11157. PubMed ID: 20585391
    [TBL] [Abstract][Full Text] [Related]  

  • 31. STAT5 activation is critical for the transformation mediated by myeloproliferative disorder-associated JAK2 V617F mutant.
    Funakoshi-Tago M; Tago K; Abe M; Sonoda Y; Kasahara T
    J Biol Chem; 2010 Feb; 285(8):5296-307. PubMed ID: 20028972
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An unusual insertion in Jak2 is crucial for kinase activity and differentially affects cytokine responses.
    Haan C; Kroy DC; Wüller S; Sommer U; Nöcker T; Rolvering C; Behrmann I; Heinrich PC; Haan S
    J Immunol; 2009 Mar; 182(5):2969-77. PubMed ID: 19234192
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain.
    Saharinen P; Vihinen M; Silvennoinen O
    Mol Biol Cell; 2003 Apr; 14(4):1448-59. PubMed ID: 12686600
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mechanisms of constitutive activation of Janus kinase 2-V617F revealed at the atomic level through molecular dynamics simulations.
    Lee TS; Ma W; Zhang X; Giles F; Kantarjian H; Albitar M
    Cancer; 2009 Apr; 115(8):1692-700. PubMed ID: 19195039
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effects of R683S (G) genetic mutations on the JAK2 activity, structure and stability.
    Li F; Guo HY; Wang M; Geng HL; Bian MR; Cao J; Chen C; Zeng LY; Wang XY; Wu QY
    Int J Biol Macromol; 2013 Sep; 60():186-95. PubMed ID: 23748007
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phosphorylated CIS suppresses the Epo or JAK2 V617F mutant-triggered cell proliferation through binding to EpoR.
    Funakoshi-Tago M; Moriwaki T; Ueda F; Tamura H; Kasahara T; Tago K
    Cell Signal; 2017 Feb; 31():41-57. PubMed ID: 28038963
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tyrosine phosphorylation of Jak2 in the JH2 domain inhibits cytokine signaling.
    Feener EP; Rosario F; Dunn SL; Stancheva Z; Myers MG
    Mol Cell Biol; 2004 Jun; 24(11):4968-78. PubMed ID: 15143188
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular basis of JAK2 activation in erythropoietin receptor and pathogenic JAK2 signaling.
    Abraham BG; Haikarainen T; Vuorio J; Girych M; Virtanen AT; Kurttila A; Karathanasis C; Heilemann M; Sharma V; Vattulainen I; Silvennoinen O
    Sci Adv; 2024 Mar; 10(10):eadl2097. PubMed ID: 38457493
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition.
    Lupardus PJ; Ultsch M; Wallweber H; Bir Kohli P; Johnson AR; Eigenbrot C
    Proc Natl Acad Sci U S A; 2014 Jun; 111(22):8025-30. PubMed ID: 24843152
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tyrosine-phosphorylated SOCS3 negatively regulates cellular transformation mediated by the myeloproliferative neoplasm-associated JAK2 V617F mutant.
    Funakoshi-Tago M; Tsuruya R; Ueda F; Ishihara A; Kasahara T; Tamura H; Tago K
    Cytokine; 2019 Nov; 123():154753. PubMed ID: 31255914
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.